Evaluating the effect of herbal mouthwash on preventing and treatment of oral mucositis in patients undergoing hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105183210N3

Enrollment

Registered

2011-10-16

Start date

2011-10-08

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral mucositis. Stomatitis and related lesions

Interventions

Intervention 1: Intervention group: treatment patients receive herbal mouthwash. patients should gargle it 3 times daily, every time diluting 1 milliliter of mouthwash in 50 milliliters water, during

Treatment - Drugs

Placebo

Intervention group: treatment patients receive herbal mouthwash. patients should gargle it 3 times daily, every time diluting 1 milliliter of mouthwash in 50 milliliters water, during the time of thei

Control group: placebo patients receive placebo mouthwash. patients should gargle it 3 times daily, every time diluting 1 milliliter of mouthwash in 50 milliliters water, during the time of their hosp

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients in Bone Marrow Transplant Center undergoing conditioning therapy. Exclusion criteria: The patients who don’t want to continue the study, Allergic reactions like hives, swollen lips and inflammation of the oral mucosa caused by plants used to prepare the herbal mouthwash.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: After intervention, daily. Method of measurement: Visual pain scale.;Ulcer. Timepoint: After intevention, daily. Method of measurement: EBMT qustionnaire.;Erythema. Timepoint: after intervention, daily. Method of measurement: EBMT questionnaire.;Swallowing ability. Timepoint: after intervention, daily. Method of measurement: EBMT questionnaire.;WBC Engraftment Time. Timepoint: At the end of the intervention. Method of measurement: Blood test.;Platelet Engraftment Time. Timepoint: At the end of the intervention. Method of measurement: Blood test.	—

Measure

Time frame

Pain. Timepoint: After intervention, daily. Method of measurement: Visual pain scale.;Ulcer. Timepoint: After intevention, daily. Method of measurement: EBMT qustionnaire.;Erythema. Timepoint: after intervention, daily. Method of measurement: EBMT questionnaire.;Swallowing ability. Timepoint: after intervention, daily. Method of measurement: EBMT questionnaire.;WBC Engraftment Time. Timepoint: At the end of the intervention. Method of measurement: Blood test.;Platelet Engraftment Time. Timepoint: At the end of the intervention. Method of measurement: Blood test.

—

Secondary

Measure	Time frame
Allergic reactions. Timepoint: After intervention, daily. Method of measurement: Outbreak of hives, swollen lips and inflammation of the oral mucosa.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSara Ghasemi

Faculty of Pharmacy, Shahid Beheshti University Of Medical Sciences

sara_ghasemi64@yahoo.com+98 21 2270 8987

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026